GLAXOSMITHKLINE PHARMA LT
Latest filings
Next results: Tue, 3 Nov · Financial Results- GSK Pharma to hold analyst and investor meeting on 4 November 2026 · Board & Shareholder Meetings
- Board meeting on Nov 3 to approve Q2 FY26 results · Results
- Compliance certificate for share dematerialisation, Q2 FY27 · Compliance
Snapshot
What the business is, and whether it's a good one at a fair price.
Markets and sells pharmaceutical products in India across three main buckets: General Medicines (brands like Augmentin and Calpol), Vaccines (Shingrix and others), and a growing Specialty/Oncology portfolio (Trelegy, Nucala, Zejula, Jemperli). FY26 standalone revenue stood at ₹3,821.67 crore with net profit of ₹1,035.98 crore, the first time PAT crossed ₹1,000 crore, and EBITDA margin of 34%, up 290 basis points year-on-year. General Medicines, the largest segment, was held flat by supply disruptions from a contract manufacturer fire (around ₹100 crore impact), while Vaccines delivered double-digit growth of around 11-12% in Q4. The innovation/specialty portfolio has scaled to 6% of Q4 sales from 2% a year ago, with a stated target of 10%, and upcoming launches include Blenrep for multiple myeloma (addressing 40,000+ prevalent patients), Bepirovirsen for hepatitis B, and an RSV vaccine. Inputs costs are dominated by employees at 15.9% of revenue and materials at 11.4%, with capex light at 1.4%, suggesting a marketing and distribution-led model rather than large-scale domestic manufacturing.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Charts
How has the market priced it — with filings on the timeline?
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from GLAXOSMITHKLINE PHARMA LT's filed financials and exchange disclosures
What does GLAXOSMITHKLINE PHARMA LT do?
GLAXOSMITHKLINE PHARMA LT is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol GLAXO.
Is GLAXOSMITHKLINE PHARMA LT profitable?
Yes. Over the trailing twelve months GLAXOSMITHKLINE PHARMA LT reported a net profit of ₹1,068 Cr on revenue of ₹3,955 Cr.
Does GLAXOSMITHKLINE PHARMA LT pay a dividend?
Yes. The dividend yield is 1.69% at the current price. It paid out 69% of its profit as dividend in FY26.
Is GLAXOSMITHKLINE PHARMA LT debt-free?
Yes. It reported no borrowings on its 31 Mar 2026 balance sheet, and ₹1,102 Cr of cash.
Is GLAXOSMITHKLINE PHARMA LT expensive compared with its peers?
On trailing P/E, GLAXOSMITHKLINE PHARMA LT ranks 104 of 158 in Pharmaceuticals — cheaper than 34% of them, against an industry median of 30.8×. This is a position, not a valuation judgement.
How much does the GLAXOSMITHKLINE PHARMA LT share price move in a day?
On a typical session GLAXOSMITHKLINE PHARMA LT moves 0.97% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.
When are GLAXOSMITHKLINE PHARMA LT's next results?
Financial Results on Tue, 3 Nov. MarketPing alerts you on WhatsApp the moment the filing lands.
Where can I track GLAXOSMITHKLINE PHARMA LT's announcements?
Every NSE and BSE filing by GLAXOSMITHKLINE PHARMA LT appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.